Group 1 - The core point of the article is that Changchun High-tech (000661) has entered into a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China [1] - Changchun Jin Sai Pharmaceutical, a subsidiary of Changchun High-tech, will have exclusive rights to three ALK-developed products in mainland China, including subcutaneous allergen preparations, skin prick test kits, and sublingual tablets [1] - The collaboration agreement grants Changchun Jin Sai Pharmaceutical exclusive rights until December 31, 2039, and involves an upfront payment of €32.7 million for the commercialization rights of the three products [1]

Core Viewpoint - Changchun High-tech (000661) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights for three products in the mainland market [1] Group 1: Partnership Details - The partnership involves Changchun High-tech's subsidiary, Jinsai Pharmaceutical, which will pay an upfront fee of €32.7 million for the collaboration [1] - Jinsai Pharmaceutical will also make a milestone payment of €40 million based on the clinical trial regulatory approval progress for the sublingual tablet (ACARIZAX) for adults, adolescents, and children in China [1] - Future payments of up to €105 million may be made depending on the sales performance of the products in the Chinese market [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech, will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - The collaboration grants Changchun Jinsai exclusive rights to three ALK-developed products in mainland China, including subcutaneous HDM allergen preparations (Acarizax), skin prick test kits (Acarizax), and sublingual tablets (ACARIZAX®) [1] - The partnership agreement is valid until December 31, 2039, and Changchun Jinsai will pay an upfront fee of €32.7 million for the commercialization rights [1]